Royalty Pharma plc (FRA:RPD)
Germany
· Delayed Price · Currency is EUR 31.04
+0.05 (0.16%)
At close: Aug 15, 2025, 10:00 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue from Intangible Royalty Assets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Revenue from Intangible Royalty Assets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Royalty Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Royalty Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cystic Fibrosis Franchise | 826.21M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cystic Fibrosis Franchise Growth | -4.86% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tysabri | 124.82M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tysabri Growth | -14.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Imbruvica | 131.09M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Imbruvica Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Xtandi | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Xtandi Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Promacta | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Promacta Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tazverik | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Products | 548.82M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Products Growth | 12.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tremfya | 147.14M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tremfya Growth | 3.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Trelegy | 146.92M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Trelegy Growth | 8.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Evrysdi | 224.43M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Evrysdi Growth | 26.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Royalty Income and | 114.15M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Portfolio Receipts | 2.80B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Portfolio Receipts Growth | 19.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|